Vaccine News and Research

Latest Vaccine News and Research

BioSante closes $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

24 Jun 2010

Company took measures to protect employees from H1N1 flu: National poll

In response to the H1N1 flu, most employees at U.S. businesses say their company took measures to protect them from illness, such as encouraging sick employees to stay home, according to a national poll of employees by researchers from the Harvard Opinion Research Program at Harvard School of Public Health.

23 Jun 2010

US physicians concerned about health risk to patients from heat-damaged medicinal products

In a recent Harris Interactive survey of US physicians about the proper storage and handling of temperature-sensitive medicines prescribed and administered to patients, physicians reported being concerned about this issue, and the overwhelming majority are concerned that heat-damaged products resulting from cumulative exposure to temperatures outside the specified temperature range pose a health risk to patients. The announcement of the study findings was made today by Temptime Corporation.

23 Jun 2010

European drugmakers lead in making medicines available to developing world, Index says

European drug companies came out ahead of their U.S. counterparts in making medicines available to people in developing countries, but their lead is beginning to shrink, according to the Access to Medicines Index, released on Monday, Reuters reports (Kelland, 6/21).

23 Jun 2010

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

ImmunoCellular Therapeutics, a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular's acquisition of Targepeutics' worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2.

23 Jun 2010

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Biovest International, Inc. (Other OTC:BVTI) today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID. At the conference, the Company reviewed positive data from an open label Phase II mantle cell lymphoma clinical trial and reported plans to meet with the FDA later this year to discuss a pathway to seek regulatory approval for this hematological indication for which there is no current consensus standard-of-care.

22 Jun 2010

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.

22 Jun 2010

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

BioSante Pharmaceuticals, Inc. commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no impact on its own ongoing development program or approval pathway for LibiGel (testosterone gel), for the treatment of hypoactive sexual desire disorder (HSDD).

22 Jun 2010

Health leaders formally launch new strategy for polio eradication

Health leaders from around the world gathered on Friday to formally launch a new strategy for eradicating polio, Newsweek's "The Human Condition" blog reports in a post examining the challenges and successes health advocates face in attempting to wipe the virus out completely (Carmichael, 6/18).

22 Jun 2010

Asthmatics to suffer more this winter warn experts

Asthma sufferers in Australia have been warned about a bad cold and flu season ahead. 58 percent of the susceptible population is already experiencing asthma attacks since the start of the season according to The National Asthma Council Australia (NACA) on Monday. They went on to say that nearly half of this population is still not vaccinated against seasonal flu.

21 Jun 2010

Also in Global Health News: WHO scraps drug development group; Access to medication in Philippines; Yellow fever vaccine shortage; HIV-positive employee protection

Lancet World Report examines how "[d]isappointment over a long-awaited report on improving drug research and development for neglected diseases" led the WHO to form a new Consultative Expert Working Group (CEWG) to strategize around drug research and development. The formation of the new group comes after the report from the previous working group (EWG) was questioned due to "what some perceived to be a missed opportunity, unclear methods, a lack of transparency and signs of industry interference" and after "suspicions of impropriety" surfaced.

21 Jun 2010

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.

21 Jun 2010

BioSante announces $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

21 Jun 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

Inovio Pharmaceuticals set to be added to Russell 3000 Index

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company is set to be added to the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, according to a preliminary list of additions updated on June 18 on www.russell.com.

21 Jun 2010

Beyond Moose and Mountains initiative focuses on building Canada's business and regulatory environment

At its 2010 annual general meeting in Montreal yesterday, the national biotechnology association, BIOTECanada, confirmed a national team of industry leaders, whose expertise will ensure Canada keeps growing what today is an $84 billion bio-economy.

21 Jun 2010

Early-life exposure to PCBs diminishes immune response to diphtheria and tetanus vaccinations: Study

Children exposed to polychlorinated biphenyls early in life later had a diminished immune response to diphtheria and tetanus vaccinations, according to a study published online June 20 ahead of print in the peer-reviewed journal Environmental Health Perspectives. This result suggests that PCB exposure during the first years of life, a critical period in immune system development, could undermine the effectiveness of childhood vaccinations and possibly impair immune system responses to infection.

21 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

SAHM strongly recommends HPV vaccines for males

On May 28, 2010, the Advisory Committee on Immunization Practices published its guidance for use of the quadrivalent HPV vaccine in males. While noting that the vaccine was approved by the FDA for use in males ages 9 through 26 to reduce their likelihood of acquiring genital warts and that it therefore could be given for this purpose, the statement released by ACIP did not recommend routine HPV vaccination of males.

19 Jun 2010

Recent releases in Global Health

The U.N.'s plan to improve maternal health is lacking "the one element that will make it work. Human rights," according to blog post on Huffington Post. "Medical causes of maternal death - hemorrhage, sepsis, hypertension, unsafe abortion, HIV and AIDS - are inextricably linked to human rights. Each one of these instances can be prevented or treated by simply respecting women's human rights in health policies and delivery of services, and addressing systemic gender inequality."

19 Jun 2010

Vaccine News and Research

Latest Vaccine News and Research

BioSante closes $15 million registered direct offering

Company took measures to protect employees from H1N1 flu: National poll

US physicians concerned about health risk to patients from heat-damaged medicinal products

European drugmakers lead in making medicines available to developing world, Index says

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

Biovest targets mantle cell lymphoma as next indication for BiovaxID

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

Health leaders formally launch new strategy for polio eradication

Asthmatics to suffer more this winter warn experts

Also in Global Health News: WHO scraps drug development group; Access to medication in Philippines; Yellow fever vaccine shortage; HIV-positive employee protection

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante announces $15 million registered direct offering

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

Inovio Pharmaceuticals set to be added to Russell 3000 Index

Beyond Moose and Mountains initiative focuses on building Canada's business and regulatory environment

Early-life exposure to PCBs diminishes immune response to diphtheria and tetanus vaccinations: Study

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

SAHM strongly recommends HPV vaccines for males

Recent releases in Global Health

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in